Your browser doesn't support javascript.
loading
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz, Andrew D; Gordon, Leo I; Abramson, Jeremy S; Advani, Ranjana H; Bartlett, Nancy L; Caimi, Paolo F; Chang, Julie E; Chavez, Julio C; Christian, Beth; Fayad, Luis E; Glenn, Martha J; Habermann, Thomas M; Lee Harris, Nancy; Hernandez-Ilizaliturri, Francisco; Kaminski, Mark S; Kelsey, Christopher R; Khan, Nadia; Krivacic, Susan; LaCasce, Ann S; Mehta, Amitkumar; Nademanee, Auayporn; Rabinovitch, Rachel; Reddy, Nishitha; Reid, Erin; Roberts, Kenneth B; Smith, Stephen D; Snyder, Erin D; Swinnen, Lode J; Vose, Julie M; Dwyer, Mary A; Sundar, Hema.
Afiliação
  • Zelenetz AD; Memorial Sloan Kettering Cancer Center.
  • Gordon LI; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Abramson JS; Massachusetts General Hospital Cancer Center.
  • Advani RH; Stanford Cancer Institute.
  • Bartlett NL; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Caimi PF; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Chang JE; University of Wisconsin Carbone Cancer Center.
  • Chavez JC; Moffitt Cancer Center.
  • Christian B; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Fayad LE; The University of Texas MD Anderson Cancer Center.
  • Glenn MJ; Huntsman Cancer Institute at the University of Utah.
  • Habermann TM; Mayo Clinic Cancer Center.
  • Lee Harris N; Massachusetts General Hospital Cancer Center.
  • Hernandez-Ilizaliturri F; Roswell Park Comprehensive Cancer Center.
  • Kaminski MS; University of Michigan Rogel Cancer Center.
  • Kelsey CR; Duke Cancer Institute.
  • Khan N; Fox Chase Cancer Center.
  • Krivacic S; Consultant.
  • LaCasce AS; Dana-Farber/Brigham and Women's Cancer Center.
  • Mehta A; O'Neal Comprehensive Cancer Center at UAB.
  • Nademanee A; City of Hope National Medical Center.
  • Rabinovitch R; University of Colorado Cancer Center.
  • Reddy N; Vanderbilt-Ingram Cancer Center.
  • Reid E; UC San Diego Moores Cancer Center.
  • Roberts KB; Yale Cancer Center/Smilow Cancer Hospital.
  • Smith SD; University of Washington/Seattle Cancer Care Alliance.
  • Snyder ED; O'Neal Comprehensive Cancer Center at UAB.
  • Swinnen LJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Vose JM; Fred & Pamela Buffett Cancer Center; and.
  • Dwyer MA; National Comprehensive Cancer Network.
  • Sundar H; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 17(6): 650-661, 2019 06 01.
Article em En | MEDLINE | ID: mdl-31200358
ABSTRACT
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular / Linfoma Difuso de Grandes Células B / Oncologia / Recidiva Local de Neoplasia País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Folicular / Linfoma Difuso de Grandes Células B / Oncologia / Recidiva Local de Neoplasia País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article